506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Completed · Not applicable

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Clinical trial to study the effectiveness of 506U78 in treating patients who have relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

Key facts

Study ID

NCT00003837

Run by

National Cancer Institute (NCI)

People needed

25

Starts

1999-09-01

Expected to finish

2007-11-01

Last updated by the study team

2013-06-20

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• H. Lee Moffitt Cancer Center and Research Institute at University of South Florida — Tampa, Florida, United States
• NCI - Pharmaceutical Management Branch — Bethesda, Maryland, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Case Comprehensive Cancer Center — Cleveland, Ohio, United States
• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.